European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL
Managed Health Care Stocks Technical Review -- WellCare Health Plans, Aetna, Centene, WellPoint, and Molina Healthcare
Editor Note: For more information about this release, please scroll to bottom.
LONDON, July 30, 2014
PISCATAWAY, N.J., July 30, 2014 /PRNewswire/ -- InnoPharma, Inc.